User login
Key clinical point: Continuing natalizumab treatment during pregnancy reduces the risk of relapse and does not increase risks to newborns.
Major finding: The annualized relapse rate among women who continued treatment after the first trimester was 0.09.
Study details: A comparison of two cohorts of women with multiple sclerosis who received treatment with natalizumab and became pregnant.
Disclosures: The authors received funding from companies such as Biogen, Merck Serono, and Teva.
Citation: Landi D et al. ECTRIMS 2019, Abstract 338.
Key clinical point: Continuing natalizumab treatment during pregnancy reduces the risk of relapse and does not increase risks to newborns.
Major finding: The annualized relapse rate among women who continued treatment after the first trimester was 0.09.
Study details: A comparison of two cohorts of women with multiple sclerosis who received treatment with natalizumab and became pregnant.
Disclosures: The authors received funding from companies such as Biogen, Merck Serono, and Teva.
Citation: Landi D et al. ECTRIMS 2019, Abstract 338.
Key clinical point: Continuing natalizumab treatment during pregnancy reduces the risk of relapse and does not increase risks to newborns.
Major finding: The annualized relapse rate among women who continued treatment after the first trimester was 0.09.
Study details: A comparison of two cohorts of women with multiple sclerosis who received treatment with natalizumab and became pregnant.
Disclosures: The authors received funding from companies such as Biogen, Merck Serono, and Teva.
Citation: Landi D et al. ECTRIMS 2019, Abstract 338.